MEDICAL TECHNOLOGY

Entrepreneur & Investor Life Science Summit

February 28, 2020



GPX^mEMBOLIC



Easy to use, novel embolic agent

FLUIDX MEDICAL TECHNOLOGY

- Minimally-invasive, localized/targeted, customized therapy
- Embolic devices: used to block blood flow in a vessel or vessel bed
- Significant opportunity: \$2Bn worldwide market; 8-10% growth
- Peripheral, interventional oncology and neurovascular embolization applications
- Wide array of uses tumors, aneurysms, aneurysm graft leaks, arterial venous malformations, bleeds, uterine fibroids, etc.
 - New applications (prostate, osteoarthritis, bariatric, etc.)
- Types of embolic devices: coils, microspheres, particles, plugs, liquids



Limitations of Current Embolics



• Embolic products available today can be difficult to use and unpredictable



GPX[™] Embolic Device

- Easy to use, controllable, versatile embolic device for highly targeted vessel occlusion
- No complex delivery technique or DMSO solvent necessary
- Simple preparation
- Compatible with common catheters & flush techniques
- Versatility casts well for distal penetration in small vessels and use with a coil for proximal "plug-like" occlusions
- Overcomes problems inherent in other embolic devices:
 - Radiopaque
 - Reduced risk of non-target embolization
 - No clogging in catheter
 - No issues with reflux on delivery









- GPX[™]: polymer-based technology consisting of a polycation, polyanion, and tantalum (radiopacity) premixed in a syringe
- The oppositely charged polymers remain dissolved in water at high salt concentrations, resulting in a flowable liquid
- The interaction strength between the oppositely charged polymers increases as GPX is injected into the blood stream and salt dissipates, forming a gel-like solid



General Principle: GPX solidifies upon injection into the blood vessel in response to decreased NaCl concentration

Strong IP Portfolio



- Robust intellectual property portfolio
- 10 issued patents
 - Polyelectrolyte composition
 - Method for vessel occlusion using polyelectrolytes
- Global, exclusive rights to University of Utah related IP
- 10+ patent applications
- Coverage in U.S., Europe, Australia, Japan, Canada

Successful In-Vivo Studies Demonstrate Versatility

- Executed several chronic animal studies:
 - GPXTM compared to other embolic devices/agents
 - GPX demonstrated superior ease of use, handling/delivery, and more effective long term occlusion compared to other devices
 - Swine model; 30 and 90-day endpoints; liver & kidney sites
 - Physicians on GPX: "beautiful delivery," "lovely," "I love this product," "love the responsiveness"
- Variety of applications studied:
 - 50+ animals, multiple research groups & facilities
 - Wide-neck aneurysms out to 28-days in rabbit model
 - AVM embolization using swine rete mirabile models
 - Use of GPX with a single coil for immediate occlusion
 - Portal vein embolization
 - Dual catheter embolization procedures ("Buddy Cath" technique) and use with balloons

Before GPX







Coil, before GPX

Coil + GPX



Aneurysm

Key Accomplishments & Awards



- Successfully scaled production leveraging third-party expertise
- Significant interest and support from embolic KOLs and clinical community
- Featured in scientific presentations at key global conferences (ISET, SIO, SIR, GEST, CIRSE)
- CRT 2020 Innovations Award Finalist (second runner-up)
- Initiated GLP animal study in late 2019



2020 Plan



- Complete GLP animal study
- Conduct first in human feasibility study
- Showcase study results at scientific conferences
- IDE submission & preparation for pivotal U.S./Europe study
- Explore other opportunities
 - Successful early concept studies for drug-loading GPX (first "loadable" liquid embolic for highly targeted drug delivery)
 - Other medical applications

Management Team & Advisors



- Seasoned leadership team includes well-known interventional physicians, proven entrepreneurs within the interventional space, and other successful industry leaders
- Libble Ginster
 - President & CEO
 - -C.R. Bard, Becton Dickinson, Merck, Ernst & Young, Lehman Brothers
 - 20+ years of marketing, strategy, M&A, product development
- Danny Smith
 - Director, R&D
 - -C.R. Bard, R&D leader at several early stage companies
 - -15+ years of R&D in med device
- Josh Jones, PhD
 - -Lead Biomedical Engineer
 - Research focus on polymers
- Michael Dake, MD
 - Senior VP, University of Arizona Health Sciences (Professor, Depts of Medical Imaging, Surgery, Medicine)
 - Previously Professor of Cardiothoracic Surgery and Director of the Catheterization and Angiography Laboratories at Stanford Med Ctr

- Shawn Fojtik
 - Co-Founder
 - Successful entrepreneur; product development & commercial experience across cardiovascular, electrophysiology, interventional oncology markets
 - 75+ combined issued and pending patents
- James McGuckin, MD
 - Co-Founder
 - Medical Director of the Philadelphia Vascular Institute, Founder and CEO of Vascular Access Centers, Co-Founder and Director of Research at Rex Medical, Chair of the Board of Endoshape and Board Member of Roxwood Medical
- Lawrence Kronick
 - Co-Founder
 - 35+ years of operational experience in cardiovascular, interventional radiology, electrophysiology, and imaging

GPX[™] Opportunity



- Significant, high growth market opportunity (\$>2bn) and expanding applications
- Minimally-invasive, localized therapy
- GPX: highly differentiated, innovative embolic agent
- Significant excitement from clinical community, key thought leaders and industry
- Industry has been very active in peripheral, interventional oncology & neurovascular spaces
 - Looking for differentiated technology and growth platforms
 - Ability to leverage commercial strengths and relationships



GPX^mEMBOLIC



Easy to use, novel embolic agent